Plasma exosomes in obesity hypoventilation syndrome patients drive lung cancer cell malignant properties: Effect of long-term adherent CPAP treatment

Masa, Juan F.; Qiao, Zhuanhong; González, Mónica; Martí, Sergi; Khalyfa, Ahamed; Kheirandish‐Gozal, Leila; Gozal, David

doi:10.1016/j.bbadis.2022.166479

Cited by 6 publications

(1 citation statement)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In colorectal cancer, a higher level of circulating sEVs was found in patients as compared to controls, and this increase was associated with a decrease in overall survival, suggesting that sEVs could represent a prognostic biomarker [ 27 ]. Circulating sEVs obtained from obesity hypoventilation syndrome (OHS) patients enhance lung adenocarcinoma tumor cell line proliferation, migration, and invasion, and these effects are at least partially reversible with adherent continuous positive airway pressure treatment [ 28 ]. However, the specific sEVs cargos in OHS patients and their responses to treatment, as well as murine models targeting some pathways through selective alterations of sEVs miRNA cargo, have not been conducted.…”

Section: Discussionmentioning

confidence: 99%

Small Extracellular Vesicles Harboring PD-L1 in Obstructive Sleep Apnea

Recoquillon,

Ali,

Justeau

et al. 2024

IJMS

View full text Add to dashboard Cite

Obstructive sleep apnea syndrome (OSA) has been associated with increased cancer incidence and aggressiveness. One hypothesis to support this association is the implication of immune response, particularly the programmed cell death pathway, formed by the receptor PD-1 and its ligand PD-L1. Recent studies have shown dysregulation of this pathway in severe OSA patients. It has also been shown that small extracellular vesicles (sEVs) carrying PD-L1 induce lymphocyte dysfunction. Thus, the aim of our study was to analyze the expression of PD-L1 on sEVs of OSA patients and to evaluate the role of sEVs on lymphocyte activation and cytotoxicity. Circulating sEVs were isolated from OSA patients and the control group. Lymphocytes were isolated from the control group. Circulating sEVs were characterized by western blot, nanotracking analysis, and flow cytometry and were incubated with lymphocytes. Our results show no differences in the quantity and composition of sEVs in OSA patients and no significant effects of sEVs in OSA patients on lymphocyte activation and cytotoxicity. These results suggest that OSA does not modify PD-L1 expression on sEVs, which does not contribute to dysregulation of cytotoxic lymphocytes.

show abstract

Section: Discussionmentioning

confidence: 99%